Treatment of Epilepsy

submitted by: alex01
Michael Rogawski (University of California, Davis) summarizes his research on the antiepileptic activity of neurosteroids (e.g. ganaxolone, allopregnanolone). They are allosteric modulators of GABAA receptors and are active in many models of epilepsy. They are expected, however, to be most effective in catamenial epilepsy, infantile spasms or adult partial seizures. National Institutes of Health (NIH) is currently sponsoring a clinical trial of progesterone (precursor of allopregnanolone)...

Neuropathic Pain Neurodegenerative Disease

submitted by: alex01

Dr. Remi Quirion (McGill University, Montreal, Quebec, Canada) described enhancement of the effects of pain-related peptides by PGE2 . This finding suggests a new, possible complimentary approach to the therapy of pain. Qurion also discussed anti-Alzheimer effect of polyphenols. This effect appears to be due not due to their antioxidant activity only. Quirion suggested the existence of membrane protein than binds polyphenols.

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.